A Study To Assess GW433908 (Fosamprenavir) Containing Regimens In HIV-1 Infected Subjects

ViiV Healthcare753 enrolled

Overview

GW433908 (fosamprenavir; FPV)is a pro-drug of amprenavir (APV) which is more water soluble and can be formulated into a tablet with a reduced pill burden (four 700mg tablets of FPV versus sixteen 150mg capsules daily for APV. This study is designed to provide additional information on long term safety and tolerability of FPV containing regimens for those subjects who received FPV in previous GlaxoSmithKline studies.

ViiV Healthcare is the new sponsor of this study, and GlaxoSmithKline is in the process of updating systems to reflect the change in sponsorship.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

753

Conditions

Infection, Human Immunodeficiency Virus

Interventions

fosamprenavir (GW433908)DRUG

ritonavirDRUG

Eligibility

Sex: ALLMin age: 13 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Male or non-pregnant/non-lactating females \>/=13 years of age (or \>/= 18 years of age according to local requirements). * Received fosamprenavir through prior participation in APV20001, APV30002, APV30003 or PRO30017 or have participated in APV30001 or other studies as deemed appropriate by the project team. Exclusion Criteria: * Permanent discontinuation of GW433908 in a previous study due to intolerance. * An active CDC Class C Event. * Any condition which, in the opinion of the investigator, would preclude a subject from participation.

Locations (24)

GSK Investigational Site

Fountain Valley, California, United States

Outcomes

Primary Outcomes

Number of Participants With Any Adverse Event (AE): Interim Analysis

An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. A list of all adverse events is reported in the "Other (Non-Serious) Adverse Events" section.

Time frame: Baseline (Day 1) up to 31 January 2006 (up to Week 264)

Number of Participants With Any Adverse Event (AE): Final Analysis

Time frame: Post January 2006; for up to 241 weeks

Change From Baseline in the Indicated Clinical Chemistry Parameters at Weeks 48, 96, 120, 132, 168, 180, 204, and 216

Fasting blood samples of participants were collected for the assessment of triglycerides (Tri.), cholesterol (Chol.), high density cholesterol (HDL), low density cholesterol (LDL), and fasting blood glucose (FBG). Change from Baseline at Weeks (W) 48, 96, 120, 132, 168, 180, 204, and 216 was calculated as the value at that particular week minus the value at Baseline (Day 1).

Time frame: Baseline (Day 1) and Weeks 48, 96, 120, 132, 168, 180, 204, and 216

Median Values of the Indicated Clinical Chemistry Parameters at Weeks 120, 180, 204, 216, and 432

Fasting blood samples of participants were collected for the assessment of triglycerides, cholesterol, high density cholesterol (HDL), low density cholesterol (LDL), and fasting blood glucose (FBG).

Time frame: Weeks 120, 180, 204, 216, and 432

Change From Baseline in the Total Cholesterol/HDL Ratio at Weeks 48, 120, 180, 204, and 216

blood samples of participants were collected for the assessment of the total cholesterol/HDL ratio. The ratio of total cholesterol/HDL was calculated by dividing the value of total cholesterol by the value of HDL. Change from Baseline at Weeks 48, 120, 180, 204, and 216 was calculated as the value at that particular week minus the value at Baseline (Day 1).

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

Secondary Outcomes

Percentage of Participants With Plasma HIV-1 Ribonucleic Acid (RNA) <400 and <50 Copies Per Milliliter at Baseline and Weeks 48, 120, 180, and 216 (MD=F and Observed)

Blood samples of participants were collected for the assessment of HIV-1RNA copies in plasma. Viral load, measured in RNA copies per milliliter of plasma, is an efficacy measure for antiretroviral drugs. In the MD=F analysis, participants who had missing data at or had discontinued the study prior to a certain time point are classified as non-responders. In the observed analysis (OA), data are presented for the number of participants still enrolled in the study at a certain time point. Participants in the NFV populations had received antiretroviral therapy prior to Baseline.

Time frame: Baseline and Weeks 48, 120, 180, and 216

Percentage of Participants With Plasma HIV-1RNA <400 and <50 Copies Per Milliliter at Baseline and Weeks 12, 24, 48, 60, 96, and 132 (MD=F and Observed)

Time frame: Baseline and Weeks 12, 24, 48, 60, 96, and 132

Percentage of Participants With Plasma HIV-1RNA <50 Copies Per Milliliter at Baseline and Weeks 120, 180, 240, 300, 360, 420, and 432 (Observed)

Time frame: Baseline and Weeks 120, 180, 240, 300, 360, 420, and 432

Cluster of Differentiation Antigen 4 (CD4+) Cell Count at Baseline and Weeks 48, 120, 168, 180, 204, and 216: Observed Analysis

Blood samples of participants were collected for the assessment of CD4+ cell count. CD4+ cells are white blood cells that are important in fighting infection. HIV infects CD4+ cells, replicates in them, and destroys them. CD4+ cell count provides a measure of the status of the immune system and to what extent it is affected by HIV.

Time frame: Baseline and Weeks 48, 120, 168, 180, 204, and 216

Cluster of Differentiation Antigen 4 (CD4+) Cell Count at Baseline and Weeks 24, 48, 96, 132, and 168: Observed Analysis

Time frame: Baseline and Weeks 24, 48, 96, 132, and 168

Median Plasma HIV-1 RNA at Baseline and Weeks 24, 48, 72, 96, 120, 144, 168, 180, 204, and 216

Blood samples of participants were collected for the assessment of plasma HIV-1 RNA.

Time frame: Baseline and Weeks 24, 48, 72, 96, 120, 144, 168, 180, 204, and 216

Median Plasma HIV-1 RNA at Baseline and Weeks 12, 24, 48, 72, 96, 132, and 168

Blood samples of participants were collected for the assessment of plasma HIV-1 RNA.

Time frame: Baseline and Weeks 12, 24, 48, 72, 96, 132, and 168

Median Plasma HIV-1 RNA at Weeks 180, 240, 300, 360, 420, and 432

Blood samples of participants were collected for the assessment of plasma HIV-1 RNA.

Time frame: Weeks 180, 240, 300, 360, 420, and 432

Number of Participants With HIV-1 Disease Progression to CDC Class C, or New CDC Class C or Death, From Baseline

The number of participants with progression of HIV-1 disease were assessed using the CDC classification of HIV-1: class A, asymptomatic or lymphadenopathy; class B: symptomatic, but not AIDS; class C, AIDS. A participant is considered to have had a disease progression if they report a CDC Class C event for the first time, if they report a new CDC Class C event, or if they experience any fatal adverse event during the study.

Time frame: Baseline (Day 1) up to 31 January 2006 (up to Week 264)

Number of Participants Enrolled in Studies APV30001 and APV300002 With the Indicated HIV-associated Conditions

The number of participants with the indicated HIV-associated conditions were assessed, excluding recurrences.

Time frame: Baseline (Day 1) up to 31 January 2006 (up to Week 264)

Number of Participants Enrolled in Study APV30003 and Other Studies With the Indicated HIV-associated Conditions

The number of participants with the indicated HIV-associated conditions were assessed.

Time frame: Baseline (Day 1) up to 31 January 2006 (up to Week 264)